Details The technical summary data is suggesting a short of APLS if it tests 36.47 with a downside target of 29.74. We should ...

Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

APLS has been the topic of a number of other reports ... valued at approximately $3,623,000. The trade was a 0.00 % decrease ...

Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following re ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Based on the one-year price targets offered by 18 analysts, the average target price for Apellis Pharmaceuticals Inc (NASDAQ:APLS) is $62.94 with a high estimate of $95 and a low estimate of $25.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today. The company’s shares closed yesterday at $27.71. According to TipRanks ...

E*TRADE might be for you if: You're looking for an all-in-one broker with low fees and physical branch locations. The platform offers thousands of mutual funds you can trade without paying hefty ...